BDBM562780 2-((2S,5R,6S)-4-Benzyl-6-(3-chlorophenyl)-5-(4-chlorophenyl)-3-oxomorpholin-2-yl)acetic acid and 2-((2R,5S,6R)-4-benzyl-6-(3-chlorophenyl)-5-(4-chlorophenyl)-3-oxomorpholin-2-yl)acetic acid::US11407721, Example 26

SMILES OC(=O)C[C@@H]1O[C@H]([C@H](N(Cc2ccccc2)C1=O)c1ccc(Cl)cc1)c1cccc(Cl)c1

InChI Key InChIKey=FWZPXOOPTXRDSU-UHFFFAOYSA-N

Data  3 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 3 hits for monomerid = 562780   

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562780(US11407721, Example 26 | 2-((2S,5R,6S)-4-Benzyl-6-...)
Affinity DataIC50: 591nMAssay Description:The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562780(US11407721, Example 26 | 2-((2S,5R,6S)-4-Benzyl-6-...)
Affinity DataIC50: 2.78E+3nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562780(US11407721, Example 26 | 2-((2S,5R,6S)-4-Benzyl-6-...)
Affinity DataIC50: 3.06E+3nMAssay Description:This assay was run using the same conditions as the HTRF1 assay except that 20 uL of GST-hMDM2 was incubated with 1.0 ul of diluted compound.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent